ABL1 BCR-ABL T315IABL1 BCR-ABL E255KABL1 BCR-ABL F317LABL1 BCR-ABL F359VABL1 BCR-ABL M244VABL1 BCR-ABL L248VABL1 BCR-ABL G250EABL1 BCR-ABL Q252HABL1 BCR-ABL Y253HABL1 Y253FABL1 BCR-ABL D276GABL1 BCR-ABL M351TABL1 BCR-ABL H396RABL1 BCR-ABL F486SABL1 BCR-ABL E255VABL1 BCR-ABL L384MABL1 BCR-ABL F359IABL1 M343TABL1 BCR-ABL F317VABL1 BCR-ABL H396PABL1 BCR-ABL L248RABL1 BCR-ABL E292LABL1 BCR-ABL F317RABL1 BCR-ABL L248R F359I
P3355
P3781
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid TumorStudy Of AG-013736 (Axitinib) In Patients With Advanced Solid TumorsClinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line TreatmentPhase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck CancerFirst In Human, Phase 1 Study of AG013736 In Patients With Solid TumorsPhase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) PatientsA Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid TumorsPhase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung CancerA Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent GlioblastomaAxitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaStudy of Axitinib and Temsirolimus in Solid TumorsPharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose AxitinibA Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell CarcinomaA Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +AxitinibStudy of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant MelanomaStudy of Axitinib in Patients With Unresectable Hepatocellular CarcinomaStudy of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid TumorsPrior Axitinib as a Determinant of Outcome of Renal SurgeryA Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaContinuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical TrialsA Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard TherapyProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingTalazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerAxitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal CancerNon - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsPembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing SurgeryToripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell CarcinomaStudy to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
P4844
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.Concise drug review: pazopanib and axitinib.Pharmacokinetic evaluation of axitinib.Systemic therapy in renal cell carcinoma: advancing paradigms.Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatmentMeta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinibImpaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell CarcinomaAxitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factorsAxitinib (Inlyta) for advanced renal cell carcinomaPhase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft]Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerToripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
P921
Q1164529-1568974A-C42C-49F5-807C-F02D24756CE8Q18556128-80B19C09-EB7D-4249-AA0F-C112D8CE3956Q18556340-E05915C3-9A38-455B-BD86-AA06C0CA960AQ1989240-99946822-7414-4C75-8781-FDE1B8296744Q3242950-0E6DA254-B0E8-40AC-9435-C15A77AE031BQ33525-938136CF-74F5-4547-9FB3-AABD87DC42E8Q56014392-95CD9C63-AA9C-4C37-887A-9A2FE4A985A8
P2176
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Aksitinib
@sh
Aksitinib
@sr
Axitinib
@vi
aksitinib
@nn
aksytynib
@pl
axitinib
@en
axitinib
@fr
أكسيتينيب
@ar
アキシチニブ
@ja
阿西替尼
@zh
type
label
Aksitinib
@sh
Aksitinib
@sr
Axitinib
@vi
aksitinib
@nn
aksytynib
@pl
axitinib
@en
axitinib
@fr
أكسيتينيب
@ar
アキシチニブ
@ja
阿西替尼
@zh
altLabel
AG 013736
@en
AG-013736
@en
AG013736
@en
Axitinib
@en
Inlyta®
@en
N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide
@en
axitinibum
@en
阿昔替尼
@zh
prefLabel
Aksitinib
@sh
Aksitinib
@sr
Axitinib
@vi
aksitinib
@nn
aksytynib
@pl
axitinib
@en
axitinib
@fr
أكسيتينيب
@ar
アキシチニブ
@ja
阿西替尼
@zh